## 

700 Application of: John G. Babish, et al

Application No : 10/789,814

February 27, 2004

SYNERGISTIC ANTHINFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE

The owner', <u>MELAPROTECHICAL LC.</u>

The owner', <u>MELAPROTECHICAL LC.</u>

The owner', <u>MELAPROTECHICAL LC.</u>

The except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number. 10/789.817 (field on 02/21/2004.

The owner's MELAPROTECHICAL ADMINISTRATION OF THE STATE AND THE STATE OF THE MELAPROTECHICAL ADMINISTRATION OF THE MELAPROTECHICAL A

granted on the reference application are commonly owned. This agreement runs with any patient granted on the instant application and

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference ₽ã.

binding upon the grantee, its successors or assigns.

WARNING: information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	[✓] Terminal disclaimer fee under 37 CFR 1.20(d) is included.	(617) 535-4108 Telephone Number	Alabak Royaee  Typed or printed name	December 9, 2010 Signature Date	2. 2 The undersigned is an attorney or agent of record. Reg. No. 59,037	i hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be frue, and further that these statements were made with the knowledge that wilfful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.	Check either box 1 or 2 below, if appropriate.  1. [] For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed pricy to the grant of any patent on the pending reference application, in the event that; any such patent granted on the pending reference application, expires for failure to pay a maintenance application, and the supplication of the string of the patent of the pending reference application. It is also the process of tailure to pay a maintenance of Eq. 18 held unenforceable, is found invalid by a court of competition fundation, is statutory disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a resummand or certificate is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.
--	---	------------------------------------	--------------------------------------	---------------------------------	---	--	---	--

Form PTO/SE/95 may be used for making this statement is signed by the assignee (owner).

Form PTO/SE/95 may be used for making this statement is segment because the public which is to rise and by the USPTO This collection of information is required by 37 CFR 1.37. The information is required to obtain or retain a benefit by the public which is to rise and by the USPTO to process an application. Confidentially is governed by 35 U SC 132 and 37 CFR 1.11 and 114. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application from the USPTO Time will vary depending upon the individual case Any comments on the amount of time you require to complete this torm and/or suggestions for reducing the burdent, should be sent to the Chief information Officer U.S. Patent and Trademark Office U.S. Department of Commercia, p.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, p.O. Box 1450, Alexandria, VA 22313-1450.